Brokers Offer Predictions for Revelation Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:REVB)

Revelation Biosciences, Inc. (NASDAQ:REVB) – Research analysts at Zacks Small Cap lowered their Q3 2024 earnings per share estimates for Revelation Biosciences in a research note issued to investors on Monday, August 12th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings per share of ($4.73) for the quarter, down from their previous estimate of ($2.73). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.54) per share. Zacks Small Cap also issued estimates for Revelation Biosciences’ Q4 2024 earnings at ($4.00) EPS, FY2024 earnings at ($16.32) EPS, Q4 2025 earnings at ($1.68) EPS and FY2025 earnings at ($7.18) EPS.

Revelation Biosciences Stock Down 0.8 %

REVB stock opened at $0.90 on Wednesday. Revelation Biosciences has a 52-week low of $0.88 and a 52-week high of $28.20. The stock’s fifty day simple moving average is $1.74 and its 200-day simple moving average is $2.38. The stock has a market capitalization of $1.46 million, a price-to-earnings ratio of -0.03 and a beta of 0.21.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.